Dolutegravir population pharmacokinetics in racially, sex- and age-diverse and antiretroviral therapy-experienced adults with HIV in the United States

By afschroeder • July 18, 2026

Khoei A, Edmonds A, Chang Y, Ramirez C, Vogan M, Poliseno A, Wolinsky S, Ho K, Brown TT, Margolick JB, Batson J, Hoffmann J, Marzinke MA, Kempf MC, Alcaide ML, Effoe J, Lahiri CD, Ofotokun I, Sheth AN, Gange S, French AL, Tamraz B, Aouizerat BE, Tien PC, Kassaye SG, DeHovitz J, Anastos K, Chew KW, Floris-Moore M, Dumond JB. Dolutegravir population pharmacokinetics in racially, sex- and age-diverse and antiretroviral therapy-experienced adults with HIV in the United States. HIV Med. 2026 Jul 17. doi: 10.1111/hiv.70278. Epub ahead of print. PMID: 42466959.

Tags: clinical pharmacology, dolutegravir pharmacokinetics, Infectious Diseases, integrase inhibitor, men with HIV, population pharmacokinetics, Publications, women with HIV

The transcription factor Ahr1 governs the recruitment of neutrophils to the brain and clearance of Candida albicans during CNS infection

Wakade RS, Solis NV, Ristow LC, Wellington M, Filler SG, Krysan DJ. The transcription factor Ahr1 governs the recruitment of neutrophils to the brain and[...]

Olorofim in Treatment of Patients With Poorly Controlled Disseminated Coccidioidomycosis : A Single-Group, Open-Label, Phase 2b, Multicenter Study

Donovan FM, Johnson RH, Patterson TF, Hoenigl M, Spec A, Sikka MK, Holland SM, Shoham S, Schaenman JM, Mehta SR, Kuran RA, Galgiani JN, Bresnik[...]

The hantavirus question we are not asking

Hensley LE, Halbrook M, Hoff NA, Merritt S, Olinger GG, Skinner B, von Fricken ME, Kindrachuk J, Rimoin AW. The hantavirus question we are not[...]